Group 1 - The vitamin concept sector rose by 1.55%, ranking 6th among concept sectors, with 48 stocks increasing in value, including Meino Biological reaching a 20% limit up [1][2] - Notable gainers in the vitamin sector included Xiwang Food, Yong'an Pharmaceutical, and Jindawei, which all hit the limit up, while Xianle Health, Oukang Pharmaceutical, and Fujilai also saw significant increases of 13.41%, 8.31%, and 6.54% respectively [1][2] - The sector experienced a net inflow of 548 million yuan from main funds, with 41 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow, led by Jindawei with 155 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jindawei, Xiwang Food, and Andisu, with net inflow ratios of 29.36%, 27.57%, and 20.19% respectively [3][4] - The trading volume and turnover rates for leading stocks in the vitamin sector were significant, with Jindawei showing a turnover rate of 4.82% and a price increase of 9.99% [3][4] - Other notable stocks included Yong'an Pharmaceutical with a 9.99% increase and a turnover rate of 31.54%, and Zhejiang Pharmaceutical with a modest increase of 0.29% [3][4]

Core Viewpoint - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, is under investigation, leading to significant stock price fluctuations and concerns about the company's operational stability [2][5]. Company Overview - Yong'an Pharmaceutical, founded in 2001, specializes in the research, production, and sales of taurine products, health foods, and special dietary foods [8]. - The company is the largest taurine production base globally, with an annual production capacity of 58,000 tons, holding approximately 50% of the market share [8]. - Despite being a major supplier for global brands like Red Bull, Nestlé, and Coca-Cola, the company's revenue has been declining, with reported revenues of 1.462 billion yuan in 2022, 973 million yuan in 2023, and 839 million yuan in 2024 [8]. Recent Developments - Following rumors of a significant price increase in taurine, Yong'an's stock experienced a surge, achieving five consecutive trading limits and a peak increase of nearly 60% within a week [2][6]. - However, the stock has since faced two consecutive trading halts, closing at 10.61 yuan per share on May 9, after the announcement of Chen Yong's investigation [2][6]. Financial Performance - The company's net profit has been under pressure, with a loss of 4.367 million yuan reported in Q1 2025, compared to a profit of 28.68 million yuan in the same period the previous year [8]. - Revenue from taurine accounted for 75.67% of the total revenue, indicating the product's critical role in the company's financial health [8]. Regulatory Environment - The investigation into Chen Yong is part of a broader trend, with multiple company executives facing scrutiny, reflecting tightening regulatory oversight in the capital market [5][6].

具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买一、买二、卖一、卖二、卖四，合 计买入金额2389.26万元，卖出金额4462.06万元，合计净卖出2072.80万元。 近半年该股累计上榜龙虎榜10次，上榜次日股价平均涨2.03%，上榜后5日平均跌6.59%。 永安药业5月9日交易公开信息 永安药业今日跌停，全天换手率25.76%，成交额7.06亿元，振幅14.23%。龙虎榜数据显示，机构净卖出 2072.80万元，营业部席位合计净卖出640.54万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-9.12%上榜，机构专用席位净卖出2072.80万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.16亿元，其中，买入成交额为4438.84 万元，卖出成交额为7152.18万元，合计净卖出2713.34万元。 资金流向方面，今日该股主力资金净流出5487.77万元，其中，特大单净流出2106.73万元，大单资金净 流出3381.04万元。近5日主力资金净流出2.31亿元。（数据宝） | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | - ...

这场代际交替中的转型突围战，既考验着接班人的战略定力，也决定着这家行业龙头能否穿越周期。 突遭留置引发连锁反应 5月5日的一纸公告，将永安药业推向了风口浪尖。公司实际控制人、董事长陈勇被立案调查并实施留 置。这一突发事件不仅引发了永安药业次日股价的"一字"跌停，也使其未来发展充满了不确定性。 对于实控人涉案的影响，公司5月8日的回应仍显模糊。永安药业表示："目前，公司尚未知悉上述事项 的进展和结论，也无法了解需要多久，公司将持续关注上述事项的进展情况，并严格按照相关规定及时 履行信息披露义务。" 紧急接棒的"85后"少帅陈子笛面临双重考验。这位金融背景出身的接班人不仅要稳住陈勇被查带来的治 理危机，还需应对牛磺酸行业的变局。尽管永安药业手握全球牛磺酸50%市场份额，但原料价格波动以 及市场产能增多，正在侵蚀其传统成本优势。 21世纪经济报道记者 李佳英 广州报道 与此同时，永安药业转型之路同样步履维艰。虽然永安药业加码肌酸、保健品等新业务，但2024年相关 板块收入均同比下滑超20%，远未形成接力牛磺酸的第二增长曲线。 一纸公告将永安药业推入风暴中心。近日，永安药业实际控制人、董事长陈勇突遭立案调查并实施留 ...

Core Viewpoint - Yong'an Pharmaceutical's stock price has experienced significant volatility, including a rapid rise followed by a sharp decline, influenced by market rumors and internal management changes [1][4]. Company Overview - Yong'an Pharmaceutical (002356.SZ) has a total market capitalization of 3.551 billion yuan as of May 7, with a recent stock price increase of 3.7% [2]. - The company primarily engages in the research, production, and sales of three categories of products: taurine, health foods, and special dietary foods (creatine) [6]. Recent Developments - The stock price surged due to rumors of a fivefold increase in taurine prices, which were later confirmed to be false by the company [4]. - On May 5, the company's chairman, Chen Yong, was placed under investigation, leading to a temporary leadership change with his son, Chen Zidi, stepping in as acting chairman [6][7]. Financial Performance - For the year 2024, Yong'an Pharmaceutical reported revenues of 839 million yuan, a year-on-year decrease of 13.78%, with taurine sales contributing 635 million yuan, accounting for 75.67% of total revenue [7]. - The net profit attributable to shareholders for 2024 was 61.766 million yuan, marking a significant increase of 601.65% compared to the previous year, indicating a turnaround from losses [7]. - In the first quarter of 2025, the company reported revenues of 171 million yuan, a decline of 12.96%, and a net loss of 4.3672 million yuan, a decrease of 115.23% year-on-year [7].

永安药业今日上涨3.70%，全天换手率35.25%，成交额10.15亿元，振幅15.09%。龙虎榜数据显示，机构 净卖出20.25万元，营业部席位合计净买入288.69万元。 近半年该股累计上榜龙虎榜9次，上榜次日股价平均涨2.55%，上榜后5日平均跌1.47%。 资金流向方面，今日该股主力资金净流入5442.80万元，其中，特大单净流入3869.52万元，大单资金净 流入1573.28万元。近5日主力资金净流入3911.06万元。（数据宝） 永安药业5月7日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 广发证券股份有限公司郑州农业路证券营业部 | 1814.51 | 6.18 | | 买二 | 机构专用 | 1543.23 | 689.34 | | 买三 | 中国银河证券股份有限公司大连人民路证券营业部 | 1317.51 | 60.21 | | 买四 | 中国国际金融股份有限公司上海分公司 | 1198.02 | 323.18 | | 买五 | 中信建投证券股份有限公司上海营口路证券营业部 ...

Core Viewpoint - The investigation of the actual controller of Yong'an Pharmaceutical, Chen Yong, comes amid unusual stock price fluctuations, raising concerns about the company's governance and financial health [2][3]. Company Investigation - Yong'an Pharmaceutical announced that its actual controller and chairman, Chen Yong, is under investigation by the Hubei Province Hefeng County Supervisory Committee and has been detained [2][3]. - Chen Yong holds 21.54% of Yong'an Pharmaceutical's shares as of the end of March this year [2][3]. - The company did not disclose the specific reasons for Chen's investigation, stating that other board members are performing their duties normally and that the company's control and operations remain unaffected [3][4]. Stock Price Fluctuations - The stock price of Yong'an Pharmaceutical experienced significant volatility, with a surge of nearly 60% over seven trading days, attributed to rumors of soaring taurine prices [2][6]. - The stock reached a peak of 14.34 CNY per share before declining to 11.62 CNY per share following the company's clarification that the rumors were untrue [6][7]. Financial Performance - Yong'an Pharmaceutical's revenue has been declining for three consecutive years, with a net loss of 4.367 million CNY reported in the first quarter of this year [2][8]. - The company's revenues for 2022, 2023, and 2024 were 1.462 billion CNY, 973 million CNY, and 839 million CNY, respectively, with net profits of 140 million CNY, -12 million CNY, and 6.2 million CNY [8]. Legal Challenges - The company is also facing long-term challenges from a cross-border lawsuit regarding patent infringement related to its taurine products [9]. - A court ruling in February 2024 found that Yong'an Pharmaceutical did not infringe on the patents claimed by VITAWORKS IP, LLC, but the case is still ongoing due to an appeal [9].

近半年该股累计上榜龙虎榜8次，上榜次日股价平均涨2.39%，上榜后5日平均跌4.10%。 资金流向方面，今日该股主力资金净流出3207.58万元，其中，特大单净流出2917.08万元，大单资金净 流出290.50万元。近5日主力资金净流出1.52亿元。（数据宝） 永安药业5月6日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 海通证券股份有限公司保定东风东路证券营业部 | 127.01 | 0.00 | | 买二 | 中泰证券股份有限公司潍坊东风西街证券营业部 | 116.20 | 0.00 | | 买三 | 国投证券股份有限公司揭阳分公司 | 100.40 | 0.00 | | 买四 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 78.67 | 0.00 | | 买五 | 东方财富证券股份有限公司上海徐汇区云锦路证券营业 部 | 69.26 | 0.00 | | 卖一 | 东莞证券股份有限公司厦门分公司 | 0.12 | 929.60 | | 卖二 | 华泰证 ...

值得一提的是，永安药业也是A股市场今年以来第11家、今年4月以来第6家披露高管被留置的上市公司。 今年2月，最高人民检察院、中国证监会在北京联合举行"依法从严打击证券违法犯罪，促进资本市场健康稳定发展"新闻发布会。中 国证监会方面人士表示，下一步，将落实好党中央、国务院决策部署，深入推进新"国九条"和资本市场"1+N"政策文件落地，强本强 基，严监严管，强化监管执法政治担当。 5月5日晚间，永安药业（002365.SZ，股价11.62元，市值34.24亿元）公告披露，公司收到公司实控人、董事长陈勇家属的通知，其于 近日收到由鹤峰县监察委员会签发的关于陈勇的《立案通知书》和《留置通知书》，陈勇被立案调查并实施留置。 每经记者 王琳 每经编辑 董兴生 《每日经济新闻》记者注意到，出生于1959年的陈勇颇为低调。此次被实施留置之前，涉及他的公开报道较少。此外，近10年来，其 从未参加过永安药业的业绩说明会和机构投资者调研接待活动。 不过，永安药业近年来业绩波动较大。财报显示，永安药业在2023年实现营业收入9.73亿元，同比下降33.48%；扣非后归母净利润亏 损7599.54万元，同比下降162.11%。到了20 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-33 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 4 月 30 日、2025 年 5 月 6 日连续两 个交易日内日收盘价格跌幅偏离值累计超出 20%，根据深圳证券交易所的有关规 定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 （二）公司于 2025 年 5 月 6 日披露了《关于公司实际控制人、董事长被留 置的公告》（公告编号 2025-31），公司实际控制人、董事长陈勇先生被立案调 查并实施留置，截至本公告披露日，公司暂未知悉上述事项的进展及结论，暂未 收到有权机关对公司的任何调查或者配合调查文件。公司具有完善的组织结构和 规范的治理体系，目前公司生产经营活动正常，公司其他董事、监 ...